Experimental models in peritoneal dialysis (Review)

BO YANG1*, MENGMENG WANG2*, XUE TONG1*, GHADA ANKAWI3, LIN SUN1 and HONGTAO YANG1

1Department of Nephrology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381; 2Department of Endocrinology, Fuyang Fourth People's Hospital, Fuyang, Anhui 236000, P.R. China; 3Department of Internal Medicine and Nephrology, King Abdulaziz University, Jeddah 21589, Saudi Arabia

Received April 30, 2020; Accepted December 15, 2020

DOI: 10.3892/etm.2021.9671

Abstract. Peritoneal dialysis (PD) is one of the most commonly used dialysis methods and plays an important role in maintaining the quality of life of patients with end-stage renal disease. However, long-term PD treatment is associated with adverse effects on the structure and function of peritoneal tissue, which may lead to peritoneal ultrafiltration failure, resulting in dialysis failure and eventually PD withdrawal. In order to prevent the occurrence of these effects, the important issues that need to be tackled are improvement of ultrafiltration, protection of peritoneal function and extension of dialysis time. In basic PD research, a reasonable experimental model is key to the smooth progress of experiments. A good PD model should not only simulate the process of human PD as accurately as possible, but also help researchers to understand the evolution process and pathogenesis of various complications related to PD treatment. To better promote the clinical application of PD technology, the present review will summarize and evaluate the in vivo PD experimental models available, thus providing a reference for relevant PD research.

Contents

1. Introduction
2. Experimental animals
3. Classification of animal PD models
4. Peritoneal function assessment
5. Choice of peritoneal dialysis catheter
6. Potential complications in the preparation of a PD model
7. Conclusion

Introduction

Peritoneal dialysis (PD) is one of the most commonly used dialysis methods in the clinic, and utilizes the nature of the peritoneum as a semipermeable membrane to exchange water and toxic solutes in the peritoneal cavity (1). Compared with hemodialysis, PD has advantages such as stable hemodynamics, lower risk of death (2) and better residual renal function preservation (3). In addition, studies have suggested that there is increased cognitive ability (4) and relatively low suicide rate (5) in patients on long-term PD treatment in comparison with patients treated with hemodialysis. Statistically, patients on PD treatment account for about 11% of the dialysis population worldwide, especially in developing countries (6). In the United States, China, and Thailand, the use of this therapy is increasing year on year (7). Nevertheless, PD treatment is still associated with significant adverse events. For example, long-term PD treatment can alter the structure and function of the peritoneum, leading to ultrafiltration failure and eventually withdrawal from PD (1). At present, risk factors in PD treatment include biocompatibility of the peritoneal dialysate, dialysis catheter factors and infection (8,9). However, due to the limitation of human experiments imposed by medical ethics, an in-depth understanding of PD is still needed. A suitable experimental model could help people better study the physiological and pathological changes in the peritoneum during PD treatment. Therefore, establishing an experimental model similar to human PD is of great significance for studying PD techniques, improving dialysis efficacy and prolonging the survival rate of patients.

2. Experimental animals

In recent years, scholars have studied and clarified the principles and characteristics of different in vitro experimental models using human tissues, and they have found that mesenchymal transformation of peritoneal mesothelial cells is closely related to peritoneal injury (10-12). In vitro models are usually obtained by culturing peritoneal mesothelial cells (13,14). This variety of model has advantages, such as relatively low cost, clear target and less confounding factors if a single cell type is used. Researchers can conduct an in vitro test of biocompatibility of the peritoneal dialysate through human peritoneal mesothelial cell culture (15).

In terms of in vivo animal models, researchers have attempted to use dogs, cats, rabbits, rats and mice to establish
PD models (16,17). However, due to the influence of many factors, such as cost and individual size of animals, different animals have specific advantages and disadvantages (Table 1). From an economic cost perspective, rats and mice are cheaper and faster to breed, while rabbits, dogs, and cats are relatively expensive and less prone to reproduce. From the perspective of surgical operation possibility, rats have a strong peritoneal defense system, while rabbits are extremely prone to peritoneal infection, although their peritoneum is the most similar to the human peritoneum. In addition, PD requires catheter insertion in the abdominal cavity, and one should note that, catheter implantation is difficult in mice due to their small size. Therefore, rats are currently considered the most suitable animal PD model because of their low economic cost, the ease of performing a surgical operation on them and as they are a relatively stable model (16,18). However, in order to achieve better experimental results, different experimental animals should be selected according to different research purposes and actual conditions.

3. Classification of animal PD models

PD models can be applied for different research purposes, including for the study of peritoneal fibrosis (19,20), peritoneal sclerosis (21) and angiogenesis (22,23), and they can be divided into a uremic PD model and a non-uremic PD model. The uremic PD model refers to catheter implantation under the condition of uremia, which is achieved by nephrectomy or drug methods (24). If the creatinine and urea nitrogen levels are 2-3 times higher than those in normal rats, it is considered as successful establishment of an uremic animal model (25,26). After the model is successfully established, peritoneal dialysate can be infused directly or through a dialysis catheter that is already implanted. There are three main methods that are commonly used at present. The first method is direct intraperitoneal injection, which can be with or without anesthesia. However, this method can easily result in unintentional injection into the abdominal wall (as opposed to the intraperitoneal cavity) or even puncture of the blood vessels, bladder or intestines (27,28); additionally, repeated injections will increase the risk of infection (Fig. 1A). The second method is to establish open access characterized by a peritoneal catheter inserted subcutaneously into the peritoneal cavity of the animal then leading from the neck. The peritoneal dialysate can be injected directly into the catheter (Fig. 1Bb) and the catheter can be used as a fixed channel. During each exchange, a new sterile catheter is inserted for dialysate infusion. Upon completion, the sterile catheter is removed and the channel is sealed (Fig. 1Bb). Establishing open access does not require anesthesia, but the incidence of infection is high, and catheter failure frequently occurs due to hardening or adhesion of the omentum (27). The third method is to establish closed access. In this method, an incision is made under the skin of the neck, the catheter is permanently retained and connected to the peritoneal cavity through a subcutaneous tunnel from the neck, and the dialysate is retained in the abdominal cavity until it is completely absorbed (Fig. 1C). This method reduces the incidence of infection. However, catheter blockage is still a problem (29).

The non-uremic model is a PD model which is directly established in normal animals. Establishment methods can be further divided into the following two types: i) Intraperitoneal injection of the peritoneal dialysate alone; and ii) clinical simulation of an indwelling peritoneal dialysis catheter (29). Both methods have their advantages and disadvantages. Compared with catheter implantation, direct intraperitoneal injection is easy to perform and can avoid damage to the PD device caused by rats biting the catheter. However, repeated puncture will cause mechanical peritoneal damage and ultimately affect the experimental results (30). The catheter implantation model can be further divided into the large omentum intact and the large omentum resection models (27). The omentum is an organ with defensive function. In a normal rat PD model, keeping the large omentum intact during the PD process can reduce the incidence of infection, however, the incidence of catheter blockage is increased (31). Goh (32) proposed that peritoneal folding is a safe and effective technique to solve the issue of catheter occlusion.

4. Peritoneal function assessment

PD models are primarily used to study structural and functional changes in peritoneal tissues after long-term exposure to the peritoneal dialysate (33). Therefore, the success of an animal PD model is crucial for subsequent research. In addition, the success or failure of the model is assessed by evaluation of the functional changes in the peritoneum. At present, the commonly used method is the peritoneal equilibrium test. The main parameters include ultrafiltration volume, creatinine, urea nitrogen, and 24 h urine protein. The most commonly used parameters for evaluating peritoneal transport function are ultrafiltration volume and glucose transport volume, which are detected after the dialysate is left in the peritoneal cavity for four hours (34,35). Of note, is that uremia itself, following nephrectomy, also affects the peritoneal structure and permeability (25,36), which should receive comprehensive consideration in specific studies.

5. Choice of peritoneal dialysis catheter

Establishing smooth PD access is an essential step for successful PD treatment. PD catheter-related factors are the crux to establish this access. PD therapy is often withdrawn early due to catheter dysfunction related to catheter displacement, occlusion (32,37) and corrosion (38). Similar problems may also be encountered during the preparation of animal models. Moreover, the biomaterial present in the catheter can also affect the peritoneal structure (39). Consequently, the selection of higher quality PD catheters and appropriate implantation position can effectively reduce the occurrence of catheterization-related complications, such as exit site infection, poor peritoneal dialysate outflow, or leakage. Ross et al (40) found a significant reduction in tissue inflammatory cells occurred when coating the peritoneal dialysis catheter with a bioactive glass, which proved to have important research value and application prospects in preventing tunnel infection caused by the peritoneal catheter. In another experimental study of non-uremic peritoneal dialysis rats (41), improvement of the material and insertion method of the PD
catheter were described. The catheter was made of a silicone tube, and there was an iodophor cap on the external catheter branch that could easily be replaced. In the anesthetized rats, the back of the neck between ears and scapulae, as well as the right-side and left-side of the back under the arcus costarum were shaved. A longitudinal incision of 2 cm was made over the skin of the left or right back, at a distance of 1 cm below the arcus costarum and 1 cm from the lateral side to the spine. This type of catheter insertion rarely causes complications such as infection and catheter dysfunction. Additionally, it has advantages, such as convenient operation, cost and practicality, which make it worthy to use (41,42).

6. Potential complications in the preparation of a PD model

Selection of a non-uremic model or a uremic model. Non-uremic models can avoid complications caused by nephrectomy and the development of uremia in animals (41). Compared with non-uremic experimental models, uremic models can better simulate the clinical peritoneal dialysis process. However, the model preparation period is long, and hemorrhage, postoperative infection, and even death may occur during this preparation process (43). Therefore, different models should be selected according to different experimental purposes and actual conditions. Commonly used methods to induce uremia include nephrectomy and drug administration (44). Nephrectomy includes double nephrectomy (43), 5/6 nephrectomy and bilateral ureter ligation. Considering the technical aspects of the experiment, preparation cycle of the model and hemorrhage/infection risk during the preparation process, 5/6 nephrectomy is often the most suitable and is frequently used (25,29,45,46). Commonly used drug methods include adenine infusion (47,48) and adriamycin infusion (49). It is worth noting that different animal species have differences in model establishment. Specifically, 5/6 nephrectomy, adenine infusion or adriamycin infusion are usually used in rats, while bilateral nephrectomy and bilateral ureter ligation are typically used in rabbits (16,44).

Infection. Among the various complications of PD, the incidence of infection is relatively high and possible infections include peritonitis, subcutaneous tunnel infection and exit site infection. Subcutaneous tunnel infection and exit site infection are common causes of catheter extraction (50), while peritonitis is the most frequent and serious complication. As described by Tăranu et al (51), changes in peritoneal morphology usually occur 3-4 years after starting PD, and they progressively aggravate with passage of time on PD. When infection occurs near the PD catheter site, pus secretion, erythema, pain or swelling and other characteristics are often evident (52). Ordinary preventive measures against infection are administration of antibiotics, such as cefazolin and penicillin. In addition, injection of heparin on a regular basis was found to have a positive effect on prevention and treatment of catheter blockage (26,45). If infection occurs, antibiotics should be actively used once the infection is confirmed. PD should be restarted after the infection is treated. In severe cases, it may be necessary to arrange for catheter replacement or even PD termination (53).

Difference in peritoneal function between animals and humans. Knowledge of the differences between the animal peritoneum and human peritoneum in terms of morphology and functions is significant. The main feature of human peritoneum is that the peritoneal area is larger than the surface area of glomerular capillaries of both kidneys, which is conducive to peritoneal solute clearance (16,29). Differences in peritoneal morphology between humans and animals will inevitably lead to differences in physiological and pathological mechanisms.

Table I. Main advantages and disadvantages of animal experimental models commonly used in peritoneal dialysis (16-18).

| Animal               | Advantages                                      | Disadvantages                           |
|----------------------|------------------------------------------------|-----------------------------------------|
| Rat                  | Easy operation, low cost and easy reproduction  | Short lifespan                          |
| Mouse                | Low cost and easy reproduction                  | Small size and short lifespan           |
| Rabbit               | Peritoneum is similar to humans and long lifespan| High price and not easy to reproduce    |
| Genetically modified mouse | Multiple possibilities of gene manipulation | Small size and short lifespan           |
| Dog                  | Long lifespan and larger size                   | High cost and not easy to reproduce     |
| Sheep                | Long lifespan and larger size                   | High cost and not easy to reproduce     |

Figure 1. Classification of animal PD models. (A) Direct intraperitoneal injection. (B) To establish open access, peritoneal dialysate injected directly into the catheter. (Bb) To establish open access, a new sterile catheter is inserted for dialysate infusion during each exchange. (C) To establish closed access, the catheter is permanently retained and connected to the peritoneal cavity through a subcutaneous tunnel from the neck. PD, peritoneal dialysis.
of peritoneal transport. Therefore, interspecific differences in peritoneal morphology should be considered when the results of animal experimental studies are extended to clinical research and application (54). Peritoneal surface area has an important effect on dialysis adequacy. Different animal models, with their different peritoneal surface area/body surface area ratios, will affect the dialysis efficiency (55). Another study found that the proportion of parietal peritoneal area in rats is larger than that in humans, that surface area of the peritoneum in lighter animals is also larger and that the surface area increases with aging in rats (56). Consequently, changes in the experimental results due to animal age and weight need to be fully considered in experimental research.

7. Conclusion

A successful PD model should simulate the clinical PD process and have characteristics including good reproducibility, feasibility and economic value. Additionally, it should also help in the process of deeply understanding the etiology and pathogenesis of PD-related diseases, providing guidance for clinical treatment and prolonging the duration where PD can be utilized as a dialysis method. There is currently no recognized standard model for studying PD, and there are great differences in the selection of animal models, administration routes, modeling methods and model evaluation methods. Moreover, due to the complexity and diversity of influencing factors in the PD process, it is often not possible to use a single experimental model for all aspects of the study. Therefore, future research is needed to establish a relatively standardized experimental PD model that is more in accordance with the clinical situation.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 81774065).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

BY, MMW and XT wrote and revised the manuscript. GA, LS and HTY reviewed and edited the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bajo MA, Del Peso G and Teitelbaum I: Peritoneal membrane preservation. Semin Nephrol 37: 77-92, 2017.
2. Mehrotra R, Devuyst O, Davies SJ and Johnson DW: The Current state of peritoneal dialysis. J Am Soc Nephrol 27: 3238-3252, 2016.
3. Krediet RT: Preservation of residual kidney function and urine volume in patients on dialysis. Clin J Am Soc Nephrol 12: 377-379, 2017.
4. Neumann D, Mau W, Wienke A and Girndt M: Peritoneal dialysis is associated with better cognitive function than hemodialysis over a one-year course. Kidney Int 93: 430-438, 2018.
5. Chen JM, Lin PH, Wu VC, Wu CS, Shan JC, Chang SS and Liao SC: Suicide deaths among patients with end-stage renal disease receiving dialysis: A population-based retrospective cohort study of 64,000 patients in Taiwan. J Affect Disord 227: 7-10, 2018.
6. Jain AK, Blake P, Cordy P and Garg AX: Global trends in rates of peritoneal dialysis. J Am Soc Nephrol 23: 533-544, 2012.
7. Li PK, Chow KM, Van de Luitjegaarden MW, Johnson DW, Jager KJ, Mehrotra R, Naikker S, Pecorini-Filho R, Yu XQ and Lameire N: Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol 13: 90-103, 2017.
8. Kitterer D, Biegger D, Segerer S, Braun N, Alschler MD and Latus J: Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis. PLoS One 12: e0177487, 2017.
9. Cho Y and Johnson DW: Peritoneal dialysis-related peritonitis: Towards improving evidence, practices, and outcomes. Am J Kidney Dis 64: 278-289, 2014.
10. Aroesti LS, Aguilera A, Selgas R, Ramírez-Huescas M, Pérez-Lozano ML, Cirugeda A, Bajo MA, del Peso G, Sánchez-Tomero JA, Jiménez-Heffernan JA, et al: Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am J Kidney Dis 46: 938-948, 2005.
11. López-Cabrera M, Aguilera A, Aroestí LS, Ramírez-Huescas M, Pérez-Lozano ML, Jiménez-Heffernan JA, Bajo MA, del Peso G, Sánchez-Tomero JA and Selgas R: Ex vivo analysis of dialysis effluent-derived mesothelial cells as an approach to unveiling the mechanism of peritoneal membrane failure. Perit Dial Int 26: 24-34, 2006.
12. Kim YL: Update on mechanisms of ultrafiltration failure. Perit Dial Int 29 (Suppl 2): S123-S127, 2009.
13. Fan YP, Hsia CC, Tseng KW, Liao CK, Fu TW, Ko TL, Chiu MM, Shi YH, Huang PY, Chiang VC, et al: The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat peritoneal dialysis-induced fibrosis. Stem Cells Transl Med 5: 235-247, 2016.
14. Büchel J, Bartosova M, Eich G, Wittenberger T, Klein-Hitpass L, Steppan S, Hackert T, Schaefer F, Passlick-Deetjen J and Schmitt CP: Interference of peritoneal dialysis fluids with cell cycle mechanisms. Perit Dial Int 35: 259-274, 2015.
15. ter Wee PM, Beelen RH and van den Born J: The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions. Kidney Int Suppl 88: S75-S83, 2003.
16. Nikitidou O, Peppa VI, Leivaditis K, Eleftheriadis T, Zarogiannis SG and Liakopoulos V: Animal models in peritoneal dialysis. Front Physiol 6: 244, 2015.
17. Ni J, Cnops Y, Debaix H, Boisde I, Verbavatz JM and Devuyst O: Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6j mouse. Kidney Int 67: 2021-2031, 2005.
18. Van Biesen W, Vanholder R and Lameire N: Animal models in peritoneal dialysis: A story of kangaroos and ostriches. Perit Dial Int 26: 571-573, 2006.
19. González-Mateo GT, Fernández-Millara V, Bellón T, Liappas G, Ruiz-Ortega M, López-Cabrera M, Selgas R and Aroestí LS: Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS One 9: e108477, 2014.
20. Xiang S, Li M, Xie X, Xie Z, Zhou Q, Tian Y, Lin W, Zhang X, Jiang H, Zhu Z, et al: Rapamycin inhibits epithelial-to-mesenchymal transition of peritoneal mesothelial cells through regulation of Rho GTPases. FEBS J 283: 2309-2325, 2016.
et al.: A new non-uremic rat model of peritoneal dialysis. BioMed Res Int 2015: 289751, 2015.

21. Li Z, Yan H, Yuan J, Cao L, Lin A, Dai H, Ni Z, Qian J and Fang W: Pharmacological inhibition of hepatic-banding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model. Clin Exp Nephrol 22: 257-265, 2018.

22. Guo J, Xiao J, Gao H, Jin Y, Zhao Z, Jiao W, Liu Z and Zhao Z: Cyclooxygenase-2 and vascular endothelial growth factor expressions are involved in ultrafiltration failure. J Surg Res 188: 527-536.e2, 2014.

23. Miller TE, Fidgon G and Rowe L: Characterization of an animal model of continuous peritoneal dialysis in chronic renal impairment. Clin Nephrol 37: 42-47, 1992.

24. Ferrantelli E, Liappas G, Keuning ED, Vila Cuenca M, González-Mateo G, Verkaik M, López-Cabrera M and Beelen RH: A novel mouse model of peritoneal dialysis: combination of ureaemia and long-term exposure to PD fluid. BioMed Res Int 2015: 106902, 2015.

25. Zareie M, De Vriese AS, Hekking LH, ter Wee PM, Slackwijk CG, Driesprong BA, Schadee-Eestermans IL, Beelen RH, Lameire N and van den Born J: Immunopathological changes in a uraemic rat model for peritoneal dialysis. Nephrol Dial Transplant 20(8): 2360-2361, 2005.

26. Peng XY, Cao QY, Li X, Liu CZ, Lindholm B and Wang T: Comparison of three chronic dialysis models. Adv Perit Dial 16: 51-54, 2000.

27. van Westrenen R, Westra WM, van den Born J, Krediet RT, Keuning ED, Hiralal J, Dragt C and Hekking LH: Alpha-2-macroglobulin and albumin are useful serum proteins to detect subclinical peritonitis in the rat. Perit Dial Int 26: 101-107, 2006.

28. Pawlaczyk K, Baum E, Schwerner K, Hoppe K, Lindholm B and Breborowicz A: Animal models of peritoneal dialysis: thirty years of our own experience. BioMed Res Int 2015: 261813, 2015.

29. Wang J, Liu S, Li H, Sun L, Zhang Z, Xu X, Liu Y, Wang Y and Miao L: A review of rodent models of peritoneal dialysis and its complications. Int Urol Nephrol 47: 209-215, 2015.

30. De Vriese AS, Mortier S, Cornelissen M, Palms E, Vanacker NJ, Leyssens A, Faict D, del Ridder L and Lameire NH: The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 22: 566-572, 2002.

31. Goh YH: Omental folding: A novel laparoscopic technique for salvaging peritoneal dialysis catheters. Perit Dial Int 28: 626-631, 2008.

32. Fabbrini P, Zareie M, Ter Wee PM, Keuning ED, Beelen RH and van den Born J: Peritoneal exposure model in the rat as a tool to unravel bio(in)compatibility of PDF. Nephrol Dial Transplant 21(Suppl 2): i88-i111, 2006.

33. Yu D, Cai Y, Qin R, Tian X, Xiao J and Zhao Z: Dialysate Creatinine Response Patterns During Peritoneal Equilibration Test and the Association Between Cardiovascular Mortality: Findings from a Prospective Cohort Study. Kidney Blood Press Rep 3: 162-169, 2018.

34. Sun Y, Zhu F, Yu X, Nie J, Huang F, Li X, Luo N, Lan HY and Wang Y: Treatment of established peritoneal fibrosis by gene transfer of Smad7 in a rat model of peritoneal dialysis. Am J Nephrol 30: 84-94, 2009.

35. Combet S, Ferrier ML, Van Landschoot M, Stoenou M, Moulin P, Miatya T, Lameire N and Devuyst O: Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 12: 2146-2157, 2001.

36. Lee M and Donovan JF: Laparoscopic omentectomy for salvage of peritoneal dialysis catheters. J Endourol 16: 241-244, 2002.

37. Kouri AM, Wilson AC and Nullescu C: A malfunctioning peritoneal dialysis catheter: Answers. Pediatr Nephrol 32: 441-442, 2017.

38. Guo W, Willen R, Andersson R, Pärsson H, Liu X, Johansson K and Bengmark S: Morphological response of the peritoneum and spleen to intraperitoneal biomaterials. Int J Artif Organs 16: 276-284, 1993.

39. Ross EA, Batisch CD, Clapp WL, Sallustio JE and Lee NC: Tissue adhesion to bioactive glass-coated silicone tubing in a rat model of peritoneal dialysis catheters and catheter tunnels. Kidney Int 69: 702-708, 2006.

40. Peng YM, Shu ZJ, Xiao L, Sun L, Tang WB, Huang Y, Liu YH, Li J, Ling GH, Xu XQ, et al: A new non-uremic rat model of long-term peritoneal dialysis. Physiol Res 60: 157-164, 2011.

41. Zhao JL, Zhang T, Shao X, Zhu JJ and Guo MZ: Curcumin ameliorates peritoneal fibrosis via inhibition of transforming growth factor-activated kinase 1 (TAK1) pathway in a rat model of peritoneal dialysis. BMC Complement Altern Med 19: 280, 2019.

42. Kajbafzadeh AM, Sabetkish N and Sabetkish S: Establishment of colonic dialysis model in uremic rats by right nephrectomy and left partial nephrectomy. J Pediatr Urol 14: 159.e1-159.e8, 2018.

43. Bao YW, Yuan Y, Chen JH and Lin WQ: Kidney disease models: Tools to identify mechanisms and potential therapeutic targets. Zool Res 39: 72-86, 2018.

44. Kakuta T, Tanaka R, Satoh Y, Ishizuka Y, Imagi R, Nangaku M, Saito A and Miyata T: Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 68: 1326-1336, 2005.

45. Gotloib L, Crasswell P, Rodella H, Oreopoulos DG, Zellerman G, Ogilvie R, Husdan H, Brandes L and Vas S: Experimental model for studies of continuous peritoneal dialysis in uremic rabbits. Nephron 31: 254-259, 1982.

46. Silva FMO, Costalongo EC, Silva C, Carreira ACO, Gomes SA, Sagayar M, Fanelli C and Noronha IL: Tamoxifen and bone morphogenetic protein-7 modulate fibrosis and inflammation in the peritoneal fibrosis model developed in uremic rats. Mol Med 25: 41, 2019.

47. Santana AC, Degaspari S, Catanos R, Delhe L, de Sá Lima L, Silva C, Blanco P, Solez K, Scavone C and Noronha IL: Thalidomide suppresses inflammation in adenine-induced CKD with uremia in mice. Nephrol Dial Transplant 28: 1140-1149, 2013.

48. Yasuda K, Park HC, Ratliff B, Addabbo F, Hatzopoulos AK, Chandler P and Goligorsky MS: Adriamycin nephropathy: A failure of endothelial progenitor cell-induced repair. J Am Pathol 176: 1685-1695, 2010.

49. Liaikopoulos V, Nikitidou O, Kalathas T, Roumeliotis S, Salmas M and Eleftheriadas T: Peritoneal dialysis-related infections recommendations: 2016 update. What is new? Int Urol Nephrol 49: 2177-2184, 2017.

50. Tarama T, Florea L, Pâduraru D, Georgescu SO, Frâncu LL and Stân C: Morphological changes of the peritoneal membrane in patients with long-term dialysis. Rom J Morphol Embryol 55: 927-932, 2014.

51. Siddiqui M, Bradford L, Kaley J, Johnson G, Kim KH, Addis K and Singh M: Noninfectious peritoneal dialysis exit site rash—an unusual case report and review of the literature. Kidney Int Rep 3: 11-13, 2017.

52. Choi J, Credit K, Henderson K, Deverkada R, Vanpelt HM, He Z and Flessner MF: Antibiotic prophylaxis in an animal model of chronic peritoneal exposure. Perit Dial Int 26: 249-258, 2006.

53. Pawlaczyk K, Kuzlan M, Wieczorzowska-Tobiś K, Pawlik-Juzków H, Breborowicz A, Knapowski J and Oreopoulos DG: Species-dependent topography of the peritoneal membrane: International (CC BY-NC-ND 4.0) License.